ChiCTR2600127109 版本V1.0 版本创建时间2026/06/24 17:37:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600127109 

最近更新日期:

Date of Last Refreshed on:

2026-06-24 17:37:27 

注册时间:

Date of Registration:

2026-06-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

三种景深延长型人工晶状体视觉质量分析

Public title:

Analysis of Visual Quality in Three Types of Extended Depth of Focus Intraocular Lenses

注册题目简写:

English Acronym:

研究课题的正式科学名称:

三种景深延长型人工晶状体视觉质量分析

Scientific title:

Analysis of Visual Quality in Three Types of Extended Depth of Focus Intraocular Lenses

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

宋慧 

研究负责人:

宋慧 

Applicant:

Song Hui 

Study leader:

Song Hui 

申请注册联系人电话:

Applicant telephone:

+86 10 86428898

研究负责人电话:

Study leader's
telephone:

+86 10 86428898

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xuehui_li01@163.com

研究负责人电子邮件:

Study leader's E-mail:

songh221@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国天津市西青区复康路251号

研究负责人通讯地址:

中国天津市西青区华苑产业区榕苑路1号

Applicant address:

251 Fukang Road, Xiqing District, Tianjin, China

Study leader's address:

1 Rongyuan Road, Huayuan Industrial Zone, Xiqing District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津医科大学眼科医院

Applicant's institution:

Tianjin Medical University Eye Hospital

研究负责人所在单位:

天津医科大学眼科医院

Affiliation of the Leader:

Tianjin Medical University Eye Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026KY-45

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津医科大学眼科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin Medical University Eye Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-06-03 00:00:00

伦理委员会联系人:

陈卓

Contact Name of the ethic committee:

Chen Zhuo

伦理委员会联系地址:

中国天津市西青区华苑产业区榕苑路1号

Contact Address of the ethic committee:

1 Rongyuan Road, Huayuan Industrial Zone, Xiqing District, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 22 86428817

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1006425222@qq.com

研究实施负责(组长)单位:

天津医科大学眼科医院

Primary sponsor:

Tianjin Medical University Eye Hospital

研究实施负责(组长)单位地址:

中国天津市西青区华苑产业区榕苑路1号

Primary sponsor's address:

1 Rongyuan Road, Huayuan Industrial Zone, Xiqing District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学眼科医院

具体地址:

中国天津市西青区华苑产业区榕苑路1号

Institution
hospital:

Tianjin Medical University Eye Hospital

Address:

1 Rongyuan Road, Huayuan Industrial Zone, Xiqing District, Tianjin, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-supported Topic

研究疾病:

年龄相关性白内障  

Target disease:

Age-related cataract

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本临床旨在对比Tecnis Symfony ZXR00、Lentis Comfort LS-313 MF15、AcrySof IQ Vivity三种景深延长型人工晶状体白内障术后视觉治疗和视功能,以期为人工晶状体的选择提供参考。  

Objectives of Study:

This clinical study aims to compare the postoperative visual quality and visual function of three types of extended depth-of-focus intraocular lenses — Tecnis Symfony ZXR00, Lentis Comfort LS-313 MF15, and AcrySof IQ Vivity — in order to provide a reference for the selection of intraocular lenses.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄50-85岁; 2. 诊断为老年性白内障; 3. 除白内障外无活动性眼病,非严重干眼症,κ角在0.5 mm以内,无瞳孔异常,3个月内无眼科手术史。

Inclusion criteria

1. Aged 50 to 85 years; 2. Diagnosed with age-related cataract; 3. No active ocular disease other than cataract, no severe dry eye disease, kappa angle ≤ 0.5 mm, no pupillary abnormalities, and no history of ocular surgery within the past 3 months.

排除标准:

1. 悬韧带稳定性降低; 2. 角膜散光高于 1.25 D; 3. 既往屈光手术病史; 4. IOL 脱位; 5. 后囊混浊或任何可能妨碍术后视力的眼部合并症(弱视、视网膜或视神经病变)等。

Exclusion criteria:

1. Reduced zonular stability; 2. Corneal astigmatism greater than 1.25 D; 3. History of prior refractive surgery; 4. Intraocular lens (IOL) dislocation; 5. Posterior capsule opacification or any ocular comorbidities that may impair postoperative visual acuity (e.g., amblyopia, retinal or optic nerve disorders).

研究实施时间:

Study execute time:

From 2026-06-24 00:00:00 To 2027-06-24 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-24 00:00:00 To 2026-07-24 00:00:00

干预措施:

Interventions:

组别:

ZXR 组

样本量:

20

Group:

ZXR group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

MF-15 组

样本量:

20

Group:

MF-15 group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

Vivity 组

样本量:

20

Group:

Vivity group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学眼科医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Medical University Eye Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

离焦曲线

指标类型:

次要指标

Outcome:

Defocus curve

Type:

Secondary indicator

测量时间点:

术后1月

测量方法:

通过标准视力表在5m处患者全矫条件下,依次添加不同度数的镜片,并记录患者能清晰辨认的最小视标对应的视力值

Measure time point of outcome:

Postoperative 1 month

Measure method:

Visual acuity was measured at 5 meters using a standard visual acuity chart. With the patient’s vision fully corrected, lenses of varying diopters were successively added, and the visual acuity value corresponding to the smallest optotype that could be clearly identified was recorded.

指标中文名:

对比敏感度

指标类型:

次要指标

Outcome:

Contrast sentivity

Type:

Secondary indicator

测量时间点:

术后1月

测量方法:

通过CSV-1000在2.5m处患者双眼全矫条件下检查明视、明眩、暗室、暗眩条件下分辨检查对比敏感度

Measure time point of outcome:

Postoperative 1 month

Measure method:

Contrast sensitivity was examined under photopic, photopic with glare, mesopic, and mesopic with glare conditions using the CSV-1000 at 2.5 meters, with the patient's both eyes fully corrected.

指标中文名:

视觉质量问卷

指标类型:

次要指标

Outcome:

VF-14questionaire

Type:

Secondary indicator

测量时间点:

术后1月

测量方法:

VF-14问卷和VOQ问卷

Measure time point of outcome:

Postoperative 1 month

Measure method:

VF-14 questionaire and VOQ questionaire

指标中文名:

视觉质量检查

指标类型:

次要指标

Outcome:

Visual quality

Type:

Secondary indicator

测量时间点:

术后1月

测量方法:

使用OQAS检查;自动获取双眼MTF Cut off,SR OSI。同一操作者重复测量 3 次取平均值。

Measure time point of outcome:

Postoperative 1 month

Measure method:

Perform examination using OQAS; automatically obtain binocular MTF Cut off and SR OSI values. Repeat measurements three times by the same operator and take the average.

指标中文名:

全眼像差

指标类型:

次要指标

Outcome:

Bilateral aberrations

Type:

Secondary indicator

测量时间点:

术后1月

测量方法:

使用iTrace测量患者术前和术后双眼角膜和全眼低阶和高阶像差。同一操作者重复测量 3 次取平均值。

Measure time point of outcome:

Postoperative 1 month

Measure method:

Corneal and total ocular lower-order and higher-order aberrations were measured preoperatively and postoperatively for both eyes using the iTrace. Measurements were repeated three times by the same operator and the average was taken.

指标中文名:

双眼裸眼和矫正远、中、近视力

指标类型:

主要指标

Outcome:

Binocular uncorrected and corrected distance, intermediate, and near visual acuity

Type:

Primary indicator

测量时间点:

术后1周、1月

测量方法:

通过标准视力表,在距离5米处分别检查患者双眼矫正和裸眼远视力,通过中近视力表,在60cm和40cm处检查双眼裸眼和矫正中、近视力

Measure time point of outcome:

Postoperative 1 month1 week and 1month

Measure method:

Visual acuity was examined using a standard visual acuity chart: uncorrected and corrected distance visual acuity for each eye at 5 meters, and uncorrected and corrected intermediate/near visual acuity for both eyes at 60 cm and 40 cm, respectively.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 50 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

如有需要,可联系主要研究者说明情况后获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

If needed, please contact the principal investigator to state your case and request access.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用预先设计的、标准化的电子病例报告表收集所有研究数据,减少手工记录错误。 所有源数据(原始检查报告、病历记录等)清晰、完整、可溯源。电子数据录入需与源数据核对一致。建立严格的数据录入、修改、核查流程。数据录入有第2人独立核查(双录入或单录入加复核)。并定期进行数据核查,包括逻辑核查、范围核查、一致性核查以及缺失值检查。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All study data will be collected using a pre?designed, standardized electronic case report form (e?CRF) to minimize manual recording errors.All source data (original examination reports, medical records, etc.) shall be clear, complete, and traceable. Electronic data entry must be consistent with the source data after verification.Strict procedures are established for data entry, modification, and review. Data entry is independently verified by a second person (dual data entry or single entry with).Regular data reviews are performed, including logical checks, range checks, consistency checks, and missing value checks.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-24 17:37:27